Loading
Alzheimer's Disease Research and Treatments / Dementia and Cognitive Impairment Research · Journal article
Journal of the American Heart Association · August 20, 2026
A consensus or society position rather than new primary data.
This is a consensus-based guidance document from the American Heart Association addressing the urgent clinical gap created by the recent availability of antiamyloid therapies for early Alzheimer disease, particularly for patients with cardiovascular comorbidities. The statement synthesises expert opinion across eight work groups to provide recommendations for clinicians across multiple specialities (prescribers, primary care, emergency personnel) on patient selection, management, and emergency care, but does not present primary research evidence or quantitative outcomes.
Expert consensus statement derived from multidisciplinary working groups. Target population for guidance: patients with early Alzheimer disease and cardiovascular risk factors or comorbidities. Expert population: 75 multidisciplinary clinicians and researchers.. Intervention: Antiamyloid therapies (AAT) for early Alzheimer disease.
75 multidisciplinary experts convened to develop consensus-based guidance for antiamyloid therapy use in patients with cardiovascular risk factors and conditions Eight work groups evaluated current evidence and developed considerations for prescribers, primary care professionals, emergency personnel, and health care system stakeholders Statement addresses shared decision-making, system-level implementation changes for dementia care, and identifies gaps requiring future research and data collection
No quantitative synthesis of underlying evidence provided in abstract; specific recommendations, safety data, and effect estimates not reported.
Clinicians across primary care, cardiology, neurology, and emergency medicine should use this statement to inform patient selection for antiamyloid therapies, coordinate care between specialities, and prepare protocols for acute neurological evaluation in patients on these drugs. The recommendations support shared decision-making and systems-level planning but require integration with institutional policies and individual patient risk assessment.
This is a consensus statement from multidisciplinary expert work groups convened by the American Heart Association to address clinical management gaps; it provides recommendations for practice but does not present original trial data or evidence synthesis.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians across primary care, cardiology, neurology, and emergency medicine should use this statement to inform patient selection for antiamyloid therapies, coordinate care between specialities, and prepare protocols for acute neurological evaluation in patients on these drugs. The recommendations support shared decision-making and systems-level planning but require integration with institutional policies and individual patient risk assessment.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: New antiamyloid therapies (AAT) for treating patients with early Alzheimer disease (AD) have become available in the past 3 years. Although AAT can be beneficial in slowing progression of AD, they also come with potentially serious side effects, particularly for patients requiring anticoagulation or thrombolysis for cardiovascular conditions. Given that most patients with AD are older and likely to have cardiovascular risk factors, there is urgent need for additional guidance for clinicians about potential risks and benefits associated with AAT for patients with cardiovascular comorbidities, best practices for management of these patients, and special considerations with respect to emergency evaluation and treatment of patients on AAT who develop acute neurological symptoms. METHODS: The American Heart Association convened 75 multidisciplinary experts for the Amyloid-Related Imaging Abnormalities Summit: Cardiovascular and Stroke Considerations for β-Amyloid Immunotherapy in AD in July 2025. These experts were divided into 8 work groups to evaluate the current evidence related to AAT usage in patients with cardiovascular risk factors and conditions and develop consensus-based guidance for clinicians. RESULTS: This statement outlines the outcomes of the Summit, including considerations for prescribers, primary care professionals, emergency personnel, and health care system stakeholders. These considerations are intended to improve identification of patients as appropriate candidates for AAT, management of patients with co-occurring AD and cardiovascular conditions, and their emergency evaluation and treatment. The statement also includes guidance for shared decision-making, implementation of system changes for improving dementia care, and recommendations for future research and data collection to add to the body of evidence for treating patients with concomitant AD and cardiovascular conditions. CONCLUSIONS: Building on lessons learned from the establishment of stroke systems of care, the consensus-based considerations outlined in this document can serve as a foundation for AD systems of care aimed at ensuring optimal use of these ground-breaking therapies.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.